SERA icon

Sera Prognostics

8.78 USD
+0.65
8.00%
At close Dec 20, 4:00 PM EST
After hours
8.78
+0.00
0.00%
1 day
8.00%
5 days
3.05%
1 month
45.61%
3 months
18.65%
6 months
23.84%
Year to date
47.07%
1 year
28.18%
5 years
-26.22%
10 years
-26.22%
 

About: Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.

Employees: 57

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

96,000% more call options, than puts

Call options by funds: $961K | Put options by funds: $1K

50% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 12

41% more capital invested

Capital invested by funds: $99.7M [Q2] → $140M (+$40.7M) [Q3]

2.43% more ownership

Funds ownership: 53.1% [Q2] → 55.53% (+2.43%) [Q3]

6% less funds holding

Funds holding: 65 [Q2] → 61 (-4) [Q3]

22% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 18

Research analyst outlook

We haven’t received any recent analyst ratings for SERA.

Financial journalist opinion

Neutral
PRNewsWire
2 weeks ago
Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting
SALT LAKE CITY , Dec. 4, 2024 /PRNewswire/ -- Sera Prognostics, Inc. , The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the results of the PRIME study were accepted as a late-breaking abstract for oral podium presentation at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting™ on January 31, 2025 at 10:15 a.m. MT . Dr. Brian Iriye – maternal-fetal medicine expert at the High Risk Pregnancy Center in Las Vegas, Nevada, and principal investigator for the PRIME study – will present the results of the full PRIME study.
Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting
Neutral
PRNewsWire
2 weeks ago
Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference
SALT LAKE CITY , Dec. 2, 2024 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 2:30 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements.
Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference
Neutral
PRNewsWire
1 month ago
Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SALT LAKE CITY , Nov. 15, 2024 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 at 4:00 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements.
Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Neutral
Seeking Alpha
1 month ago
Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript
Sera Prognostics Inc (NASDAQ:SERA ) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Peter DeNardo - IR Evguenia Lindgardt - President, CEO & Director Austin Aerts - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Third Quarter Fiscal Year 2024 Results. [Operator Instructions] As a reminder, the call is being recorded for replay purposes.
Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago.
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates
Neutral
PRNewsWire
1 month ago
SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
SALT LAKE CITY , Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024. Recent Highlights: Data analysis for full Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study underway after database was locked in September and now seeking publication of results in connection with key pregnancy and maternal health conferences in early 2025 and manuscript submission to a quality peer-reviewed journal.
SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
Neutral
Benzinga
1 month ago
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Neutral
PRNewsWire
1 month ago
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024
SALT LAKE CITY , Oct. 28, 2024 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024
Neutral
PRNewsWire
3 months ago
Sera Prognostics to Present at H.C. Wainwright 26th Annual Global Investment Conference
SALT LAKE CITY , Sept. 4, 2024 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C.
Sera Prognostics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Neutral
Seeking Alpha
4 months ago
Sera Prognostics, Inc. (SERA) Q2 2024 Earnings Call Transcript
Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Zhenya Lindgardt - President & CEO Austin Aerts - CFO Conference Call Participants Andrew Brackmann - William Blair Dan Brennan - TD Cowen Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review second quarter fiscal year 2024 results. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.
Sera Prognostics, Inc. (SERA) Q2 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™